First-in-human assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the phase 1 PAnTHa study. Visual PSMA-PET and ...

A systematic review found that genomic classifier tests can influence risk assessments and treatment decisions among patients with localized prostate cancer but studies evaluating these tests vary ...

An artificial intelligence (AI) model performed better than Gleason grading and the Cancer of the Prostate Risk Assessment Post-Surgical (CAPRA-S) method when analyzing histopathology images and ...

Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population; PSMAddition ...

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma The Metformin Active Surveillance Trial (MAST) was a multicenter, randomized, double-blind, placebo-controlled phase III trial ...

Basal-luminal classifiers, such as PAM50, may predict prostate cancer grade progression risk in men with low- to intermediate-risk prostate cancer who are considering active surveillance.

Advanced prostate cancer is cancer that has spread beyond the prostate to distant parts of the body. It is also called metastatic or stage 4 prostate cancer. While most advanced prostate cancer is ...

New prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of Medicine of USC has yielded discoveries that could improve screening and ...

Scientists from UCLA, the University of Toronto and the University of Melbourne have uncovered new genetic clues that explain why some prostate cancers remain slow-growing while others become ...